Smartsheet, the AI-powered, enterprise-grade work management platform, today unveiled Smartsheet Regions Australia, a new ...

This investment in a new Smartsheet Regions Australia underscores our dedication to the APJ region and the local data residency needs of our ...

It's the seventh approved indication for the IL4 and IL13-inhibiting monoclonal antibody, which is already a blockbuster for Sanofi. CSU has also not had a new treatment approved in more than a ...

and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi ...

Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer. Precision medicine research ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Article Views are the COUNTER-compliant sum of full text article downloads since ...